U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H25BrN2O3.C4H4O4
Molecular Weight 549.411
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of BROVINCAMINE FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.[H][C@]12N3CCC[C@@]1(CC)C[C@@](O)(N4C5=CC(Br)=CC=C5C(CC3)=C24)C(=O)OC

InChI

InChIKey=CKCVTPQYFOMHFD-HPJCWFBOSA-N
InChI=1S/C21H25BrN2O3.C4H4O4/c1-3-20-8-4-9-23-10-7-15-14-6-5-13(22)11-16(14)24(17(15)18(20)23)21(26,12-20)19(25)27-2;5-3(6)1-2-4(7)8/h5-6,11,18,26H,3-4,7-10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t18-,20+,21+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C21H25BrN2O3
Molecular Weight 433.339
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Brovincamine also known as brovincamine fumarate (BV, Sabromin) was used in Japan mainly as an improver of cerebral circulation and metabolism, and also as an inhibitor of the aggregation of platelets through the cyclic AMP pathway in patients with normal tension glaucoma. Brovincamine exerts its action via calcium channels blockade. The current drug status is unknown.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Determination of 11-bromovincamine in human plasma by high-performance liquid chromatography.
1982 Mar 12
Patents

Sample Use Guides

20 mg three times daily.
Route of Administration: Oral
In Vitro Use Guide
Possible mode of vasodilative action of brovincamine was assessed in isolated cardiovascular preparations in comparison with verapamil and papaverine. Brovincamine (IC50: 1.2 x 10(-5)M) caused a dose-dependent relaxation of potassium (30 mM)-contracture in the rabbit pulmonary arterial segment. This relaxation was antagonized by increasing external Ca2+ concentration to 12.4 mM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:00:57 GMT 2023
Edited
by admin
on Fri Dec 15 19:00:57 GMT 2023
Record UNII
Y3SNC78UTU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BROVINCAMINE FUMARATE
JAN   WHO-DD  
Common Name English
BROVINCAMINE HYDROGEN FUMARATE [MI]
Common Name English
Brovincamine fumarate [WHO-DD]
Common Name English
BROVINCAMINE FUMARATE [JAN]
Common Name English
BROVINCAMINE HYDROGEN FUMARATE
MI  
Common Name English
EBURNAMENINE-14-CARBOXYLIC ACID, 14,15-DIHYDRO-11-BROMO-14-HYDROXY-, METHYL ESTER, (3-.ALPHA.,14-.BETA.,16-.ALPHA.)-, (E)-2-BUTENEDIOATE (1:1) (SALT)
Common Name English
Code System Code Type Description
SMS_ID
100000085144
Created by admin on Fri Dec 15 19:00:57 GMT 2023 , Edited by admin on Fri Dec 15 19:00:57 GMT 2023
PRIMARY
EVMPD
SUB00883MIG
Created by admin on Fri Dec 15 19:00:57 GMT 2023 , Edited by admin on Fri Dec 15 19:00:57 GMT 2023
PRIMARY
MERCK INDEX
m2730
Created by admin on Fri Dec 15 19:00:57 GMT 2023 , Edited by admin on Fri Dec 15 19:00:57 GMT 2023
PRIMARY Merck Index
CAS
84964-12-5
Created by admin on Fri Dec 15 19:00:57 GMT 2023 , Edited by admin on Fri Dec 15 19:00:57 GMT 2023
PRIMARY
PUBCHEM
5282434
Created by admin on Fri Dec 15 19:00:57 GMT 2023 , Edited by admin on Fri Dec 15 19:00:57 GMT 2023
PRIMARY
FDA UNII
Y3SNC78UTU
Created by admin on Fri Dec 15 19:00:57 GMT 2023 , Edited by admin on Fri Dec 15 19:00:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL165643
Created by admin on Fri Dec 15 19:00:57 GMT 2023 , Edited by admin on Fri Dec 15 19:00:57 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY